secwatch.observer — SEC 8-K summary
======================================

Issuer:     Molecular Templates, Inc. (—)
CIK:        0001183765
Form:       8-K
Filed at:   2024-10-11T23:59:59+00:00
Accession:  0001193125-24-236770
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Molecular Templates board approves dissolution, expects no value for shareholders
--------------------------------------------------------------------------------

- Board unanimously approved liquidation and wind-up subject to stockholder approval; no viable strategic alternatives found.
- Company does not expect stockholders to receive any value for their shares in dissolution.
- Reduction in force of substantially all employees; Phase 1 studies for MT-6402 and MT-8421 to be wound down.
- Discussions with FDA on MT-0169 for autoimmune indications to continue; Rock Creek Advisors engaged.
- Negligible costs expected for reduction in force; substantially complete in October 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/0001193125-24-236770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1183765/000119312524236770/d840872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-236770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer